Gilenya approved in Russia, awaits FDA decision
September 16, 2010Sales and Marketing Cladribine, Gilena, MS
Novartis has won approval for its MS drug Gilenya in Russia but still awaits the FDA’s decision on its fate …
Pepscan and Tibotec sign peptides deal
September 15, 2010Research and Development, Sales and Marketing CLIPS, HIV, J&J, JJ, Pepscan, Tibotec
Pepscan Therapeutics, the biotech firm focusing on protein mimicry technology has signed a deal with Tibotec. Netherlands-based Pepscan will use …
FDA warns BMS over manufacturing plant in Puerto Rico
September 15, 2010Manufacturing and Production BMS, FDA, GMP, Puerto Rico
A plant operated by Bristol-Myers Squibb in Puerto Rico has been cited by the US Food and Drug Administration for …
New Commercial Realities – Part 1: Key drivers of the evolving pharmaceutical landscape
September 15, 2010Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …
New Commercial Realities – Part 1: Key drivers of the evolving pharmaceutical landscape
September 15, 2010Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …
New Commercial Realities – Part 1: Key drivers of the evolving pharmaceutical landscape
September 15, 2010Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …
New Commercial Realities – Part 1: Key drivers of the evolving pharmaceutical landscape
September 15, 2010Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …
Digital Pharma: Boehringer gets social with Facebook
September 14, 2010Medical Communications Boehringer, Digital Pharma blog, Facebook
Boehringer Ingelheim is looking for fans on Facebook and wants its employees to be thought of as “superheroes, only with …
Positive results for irritable bowel syndrome drug
September 14, 2010Research and Development Almirall, IBS, linaclotide
A new treatment for patients with irritable bowel syndrome with constipation has produced promising results in a phase III trial. …
iPhone app is download hit for Doctors.net.uk
September 14, 2010Medical Communications Doctors.net.uk, doctors, iphone, tala, tim ringrose
An app launched by Doctors.net.uk in response to a surge in the number of doctors signing up for iPhones, has …
Future of Roche diabetes trial uncertain
September 14, 2010Research and Development GLP-1, Roche, taspoglutide
Roche has admitted it does not know when phase III trials of the investigational type II diabetes drug taspoglutide will …
Growth slowdown predicted for pharma packaging
September 14, 2010Manufacturing and Production packaging, pharma packaging
New regulatory requirements in the US are driving growth in the country’s pharmaceutical packaging market, according to market research firm …
Novasep appoints new supervisory board chairman
September 14, 2010Manufacturing and Production Novasep, appointment, manufacturing and production
French contract manufacturing firm Novasep has appointed Bernard Dubois to its top management team. Most recently a consultant, Bernard formerly …
Genzyme planning 1,000 job cuts
September 14, 2010Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, job cuts
Genzyme has said it intends to cut back its workforce by around 1,000 over the next 15 months in order …
GSK launches global joint pain education programme
September 13, 2010Medical Communications chronic pain, disease awareness campaigns, osteoarthritis
GlaxoSmithKline has launched a global education programme to help sufferers from musculoskeletal conditions such as arthritis to self-manage pain in …
Zactima extends progression free survival in other thyroid cancers
September 13, 2010Research and Development thyroid cancer, zactima
New data suggests patients with the more common forms of thyroid cancer respond to AstraZeneca’s Zactima. The drug has already …
NICE won’t approve Abilify without more data
September 13, 2010Sales and Marketing Abilify, BMS, NICE
NICE is unlikely to approve Bristol-Myers Squibb’s schizophrenia drug Abilify unless the company can provide more data on its clinical …
Countdown to Launch
September 13, 2010Sales and Marketing marketing, product launch
When NASA launches a rocket, most of the hard work is already done. The flight itself is relatively short, yet …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
